Skip to main content

Table 3 Interview respondents’ views on motivation for patient segmentation

From: Personalized medicine in Europe: not yet personal enough?

Benefits

Experts

Avoiding side effects/optimize side effect profile

Academics (3), clinical experts (2), economic experts (3), EFPIA representative (1), patient representatives (2)

Avoiding waste of resources/over-treating/selecting only patients who need it

Academic (1), clinical experts (2), economic experts (3), EFPIA representative (1), patient representatives (2), payer (1)

Improved outcomes in terms of effectiveness/efficacy

Academic (1), clinical expert (1), economic experts (3), patient representative (1), payer (1)

Better outcome/benefit/response rate (not specified)

Academic (1), clinical experts (2), economic experts (2), provider (1)

Improved cost-effectiveness/value for money

Clinical expert (1), economic experts (3), payer (1)

Reduce costs

Economic experts (3), payer (1)

Improved length of life

Academic (1), clinical expert (1), economic expert (1)

Improved quality of life

Academic (1), economic expert (1)

Free-up time from clinicians

Patient representative (1), payer (1)

  1. EFPIA, the European Federation of Pharmaceutical Industries and Associations